You are here: Industry Insights > Almac

News List

Almac, PILA PHARMA Enter API Manufacturing Pact contractpharma
August 12, 2021
Almac will manufacture XEN-D0501, a highly selective and very potent small molecule TRPV1 antagonist for ongoing type 2 diabetes clinical studies.
Almac, THREAD to Integrate Technologies for Clinical Trials contractpharma
July 29, 2021
Integrating technology platforms aims to provide sponsors and CROs with a full range of tools designed to reduce the risk of trial delays.
Almac's Charnwood site achieves H&S and environmental certification prnewswire
July 12, 2021
The CDMO plans to roll out the ISO 45001 and ISO 14001 certification throughout multiple sites worldwide
Almac’s Charnwood Site Receives ISO Certifications contractpharma
July 07, 2021
Achieves globally recognized Health & Safety and Environmental Management System certifications.
Almac Invests $830M to Expand Crystallization Capabilities contractpharma
July 02, 2021
Almac Sciences has invested approximately $485 million in an automated crystallization platform to support solid form screening of polymorphs, salts and crystals in addition to crystallization of amorphous materials.
Almac Group Completes $7M R&D Center contractpharma
February 24, 2021
Almac Sciences, a member of the Almac Group, has completed a roughly $7 million investment in a new two-storey center for biocatalysis, flow chemistry technologies and peptide research and development.
Almac Expands Global Biologics Testing Services contractpharma
January 28, 2021
Almac Sciences, a member of the Almac Group, has expanded its biologics testing laboratory with significant investment in mass spectrometry equipment.
Almac Secures Grant for Remdesivir Manufacturing for COVID-19 americanpharmaceuticalreview
December 01, 2020
Almac Sciences has been awarded a grant of approximately $500,000 by the COVID-19 Therapeutics Accelerator towards developing cost effective, scalable processes for the production of the active pharmaceutical ingredient (API) of the drug remdesivir.
Almac Gets Grant From COVID-19 Therapeutics Accelerator contractpharma
November 19, 2020
Almac Sciences has been awarded a grant of approximately $500,000 by the COVID-19 Therapeutics Accelerator towards developing cost effective, scalable processes for the production of the active pharmaceutical ingredient (API) of the drug remdesivir.
Almac Launches Biologics Testing Services contractpharma
September 27, 2020
New services include GMP lot release and stability testing to support drug substance and drug product programs for biologics and biosimilars.

Previous page 1 2 Next page